GMP-like Manufacturability Study of On-dose Anticounterfeiting Technology
PUBLIC INFORMATION SUMMARY
The increasing prevalence of counterfeit prescription products in the United States is a rising cause of concern. CertiRx Corporation is developing product authentication technology covered under US Pat. No. 7,874,489 and other pending applications, which will allow ready identification of counterfeits and more effective tracking of lost, damaged, stolen, or diverted goods.
During this project we intend to demonstrate a commercially viable manufacturing method for solid oral dosage formulations containing CertiRx authentication technology. In addition we will manufacture encoded dosage prototypes that will be used in the quantitative performance assessment of the CertiRx proprietary hardware and software.